Reduced SARS-CoV-2 entry factors and enhanced innate immune gene expression in the nasal epithelium of pregnant rats

An enigmatic epidemiological feature of the ongoing COVID-19 pandemic is the high rate of asymptomatic infection in pregnant women.1 This is puzzling because systemic immune changes predispose pregnant women to increased severity of respiratory viral infections, especially influenza A.2 A major roadblock in understanding this atypical clinical presentation is the poor characterization of cellular entry factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) — angiotensin-converting enzyme 2 (ACE2) and the androgen-sensitive transmembrane protease serine 2 (TMPRSS2) — in the respiratory tract during pregnancy.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Research Letter Source Type: research

Related Links:

NEW BRUNSWICK, N.J., July 1, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson &Johnson COVID-19 vaccine to...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
Pregnant women have long been recognized as a vulnerable population during infectious disease pandemics. This was recognized in 1918, during the Spanish influenza pandemic, in which 50% of pregnant women who were infected died. Despite the many advances in critical care since then, similar findings were noted during the 2009 H1N1 pandemic, in which pregnant women were disproportionately more likely to have severe illness, require hospitalization and intensive care, and die than their nonpregnant counterparts. Similar findings were noted during the more geographically contained novel coronavirus experiences during the past ...
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson &Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson &Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
New Brunswick, NJ (April 2, 2021) – Johnson &Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson &Johnson. “It is vital that we develop vaccines for everyo...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson &Johnson has come to the aid of people during times of crisis, and we believe tod...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection agains...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
Pregnant women have an increased risk of infectious diseases, including respiratory infections such as influenza, 2 External 0 0 0 1 false https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.21369?guestAccessKey=a0cf9d09-e1c7-479d-9aaa-a2d925aea316&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=120720#jld200113r1 true false%> and are included on the coronavirus disease 2019 (COVID-19) UK clinically vulnerable list. 2 External 0 0 0 2 false https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.21369?guestAccessKey=a0cf9d09-e1c7-479d-9aaa-a2d9...
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
The current coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the worst pandemic since the 1918 influenza pandemic (1). This novel viral infection, first reported in December 2019 in Wuhan, China, spread around the world in just a few months, causing an overwhelming international health crisis that could affect up to one-third of humanity (1,2). COVID-19, which causes fever and mild to severe respiratory symptoms, is closely related to other coronaviruses (CoVs), such as SARS (SARS-CoV-1) and MERS-CoV (Middle East respiratory syndrome CoV) (1).
Source: Biological Psychiatry - Category: Psychiatry Authors: Tags: Correspondence Source Type: research
In conclusion, we found that regardless of the presence of multimorbidity, engaging in a healthier lifestyle was associated with up to 6.3 years longer life for men and 7.6 years for women; however, not all lifestyle risk factors equally correlated with life expectancy, with smoking being significantly worse than others. A Hydrogel Scaffold to Encourage Peripheral Nerve Regeneration https://www.fightaging.org/archives/2020/10/a-hydrogel-scaffold-to-encourage-peripheral-nerve-regeneration/ The nervous system of mammals is poorly regenerative at best. The use of implantable scaffold materials is one of the...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
An enigmatic epidemiologic feature of the ongoing coronavirus disease 2019 pandemic is the high rate of asymptomatic infection in pregnant women.1 This is puzzling because systemic immune changes predispose pregnant women to increased severity of respiratory viral infections, especially influenza A.2 A major roadblock in understanding this atypical clinical presentation is the poor characterization of cellular entry factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) —angiotensin-converting enzyme 2 (ACE2) and the androgen-sensitive transmembrane protease serine 2 (TMPRSS2)—in the respirato...
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Research Letter Source Type: research
More News: Coronavirus | COVID-19 | Epidemiology | Flu Pandemic | Genetics | Influenza | OBGYN | Pandemics | Pregnancy | Respiratory Medicine | SARS | Women